search
Back to results

'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial (TOTAL)

Primary Purpose

Hernia, Hernia, Diaphragmatic, Hernia, DIaphragmatic, Congenital

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
GoldBal2 detachable balloon
Baltaccidbpe100 Delivery Catheter
Standardized postnatal care
Sponsored by
Michael A Belfort
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hernia focused on measuring CDH, Congenital Diaphragmatic Hernia, Fetal Tracheal Occlusion, FETO, plug-unplug, GoldBal2, Balloon, Goldvalve Balloon, TOTAL

Eligibility Criteria

18 Years - 64 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients aged 18 years or more, who are able to consent,
  2. Singleton pregnancy,
  3. Chromosomally normal fetus,
  4. Gestation at randomization prior to 31 weeks plus 5 days or so that occlusion is done at the latest on 31 weeks plus 6 days,
  5. Fetus is estimated to have moderate pulmonary hypoplasia, defined prenatally as:

    • O/E LHR 25-34.9% (included; irrespective of the position of the liver) • O/E LHR 35-44.9% (included) with intrathoracic liver herniation as determined by ultrasound or MRI.

    The O/E LHR will be determined by the FETO centers as follows:

    • Measurement of the contralateral lung area preferentially by the tracing method at the 4-chamber view of the heart; if by other method adjusted normative ranges must be used.
    • Measurement of the head circumference at the standard biparietal view of the head
    • The observed lung area: calculation of the LHR as the ratio of the measurements of the lung area to head circumference
    • The expected lung area is the lung area of a normal gestational age match, as determined by the head circumference of the index case in a normogram established for the same measurement method (tracing method in this case). A calculator for this will be available on the website of the study.
    • Calculation of the observed over expected lung area,
  6. Acceptance of randomization and the consequences for the further management during pregnancy and thereafter, this includes the required observation following FETO surgery, which lasts up to 4 weeks after balloon is in place,
  7. The patients must undertake the responsibility for either remaining close to, or at the FETO center, or being able to travel swiftly and within acceptable time interval to the FETO center until the balloon is removed. Intended postnatal treatment center must subscribe to suggested guidelines for "standardized postnatal treatment," and
  8. Provide written consent to participate.
  9. Fetus with no major anomalies that would impact the clinical course or outcomes.

Exclusion Criteria:

  1. Maternal contraindication to fetoscopic surgery or severe medical condition in pregnancy that make fetal intervention risky,
  2. Technical limitations precluding fetoscopic surgery, such as severe maternal obesity, uterine fibroids or potentially others, not anticipated at the time of writing this protocol,
  3. Preterm labor, cervix shortened (<15 mm at randomization) or uterine anomaly strongly predisposing to preterm labor, placenta previa,
  4. Patient age less than 18 years,
  5. Psychosocial ineligibility, precluding consent,
  6. Diaphragmatic hernia: right-sided or bilateral, major anomalies, isolated left-sided outside the O/E LHR limits for the inclusion criteria, and
  7. Patient refusing randomization, to comply with required 4-week observation after balloon placement, or to comply with return to FETO center during the time period the airways are occluded or for elective removal of the balloon.
  8. Patient allergic to latex.

Sites / Locations

  • Baylor College of Medicine/Texas Children's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

Standardized postnatal care (Expectant)

Prenatal Intervention (FETO)

Arm Description

Mothers will be expectantly managed during pregnancies and babies receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website.

Patients will undergo fetoscopic endoluminal tracheal occlusion and ideally prenatal reversal of the occlusion followed by standardized postnatal care as in the expectant . In this study FETO (where GoldBal2 detachable balloon and Baltaccidbpe100 Delivery Catheter are used) is to be done between 30 weeks plus 0 day and 31 weeks plus 6 days and removal of the balloon at 34 weeks plus 0 day to 34 weeks plus 6 days.

Outcomes

Primary Outcome Measures

Proportion of Neonate Survival at Discharge From Hospital
The null hypothesis to be tested is that there is no difference in survival between fetuses managed expectantly during pregnancy versus those undergoing antenatal therapy (FETO).
Participants Requiring Supplemental Oxygen
The number of survivors requiring supplemental oxygen at 6 months of age

Secondary Outcome Measures

Grade of Oxygen Dependency
Measured as FiO2 (oxygen) amount required as a grade (0-III) with Grade 0 indicating the best outcome and Grade III indicating the worst outcome. Grade 0 = No Bronchopulmonary Dysplasia (BPD); Grade I = FiO2 21% or room air; Grade II = FiO2 22-29%; Grade III = FiO2 >29%, CPAP or mechanical ventilation.
Occurrence of Severe Pulmonary Hypertension
Occurrence of severe pulmonary hypertension in the neonatal period.
ECMO (Extracorporeal Membrane Oxygenation) Support
Need for extracorporeal membrane oxygenation (ECMO) in the neonatal period
CDH Defect Size
Postnatal grade classification (A-D) using CDH study group standardized system with A being the smallest defects and D being the largest defects. A = Defect entirely surrounded by muscle; B = Small (<50%) portion of the chest wall devoid of diaphragm tissue; C = Large (>50%) portion of the chest wall devoid of diaphragm tissue; D = Complete or near complete absence of the diaphragm.
Number of Days in the NICU
Length of stay in the neonatal intensive care unit measured in days
Ventilatory Support
Length of time participants required ventilator support measured in days.
Number of Subjects With Periventricular Leukomalacia (PVL)
As measured by presence in medical record ≤ 2 months postnatally by ultrasound (yes/no)
Neonatal Sepsis
As measured by presence in medical record
Intraventricular Hemorrhage
Measured as presence in neonate during first month by MRI and/or ultrasound.
Retinopathy of Prematurity
Postnatal grade classification presence of grade III or higher using standardized system (yes/no)
Days to Full Enteral Feeding
The number of days until full enteral feeding
Gastroesophageal Reflux
Presence of reflux above 1/3 of esophagus on clinically indicated radiologic exam
CDH (Congenital Diaphragmatic Hernia) Surgery Repair
How many days from birth until the surgery is performed to repair the defect.
Use of Patch in CDH Repair
The number of participants who had a patch used in the repair of the CDH defect.
Survival
The number of participants that survived to 24 months of age

Full Information

First Posted
August 5, 2016
Last Updated
May 31, 2022
Sponsor
Michael A Belfort
Collaborators
Baylor College of Medicine, Universitaire Ziekenhuizen KU Leuven
search

1. Study Identification

Unique Protocol Identification Number
NCT02875860
Brief Title
'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial
Acronym
TOTAL
Official Title
TOTAL TRIAL: Randomized Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) Versus Expectant Management During Pregnancy in Fetuses With Left-Sided and Isolated Congenital Diaphragmatic Hernia and Moderate Pulmonary Hypoplasia
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
January 2017 (undefined)
Primary Completion Date
October 2019 (Actual)
Study Completion Date
October 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Michael A Belfort
Collaborators
Baylor College of Medicine, Universitaire Ziekenhuizen KU Leuven

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This trial will test whether temporary fetoscopic endoluminal tracheal occlusion (FETO) rather than expectant management during pregnancy, followed by standardized postnatal management, increases survival at discharge and decreases oxygen need at 6 months in case of survival till discharge.
Detailed Description
This is a multi-center, non-blinded randomized controlled trial in fetuses with isolated moderate CDH, i.e. moderate lung hypoplasia (as determined by prenatal assessment of lung development). It essentially compares fetal therapy added to conventional postnatal care, versus expectant prenatal management during pregnancy followed by conventional postnatal care. Enrollment: Following completion of an inclusion/exclusion criteria checklist and obtaining informed consent, the subject will be randomized into two groups ("FETO" and "expectant"). Procedures: Group I: Standardized postnatal care (expectant group): mothers will be expectantly managed during pregnancies and babies receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. Group II: Prenatal intervention (FETO group): patients will undergo fetoscopic tracheal occlusion and ideally prenatal reversal of the occlusion followed by standardized postnatal care as in I. In this study FETO is to be done between 30 weeks plus 0 day and 31 weeks plus 6 days and removal of the balloon at 34 weeks plus 0 day to 34 weeks plus 6 days. This study trial is a pragmatical or efficacy trial: ideally mothers will deliver after removal of the balloon at those tertiary centers, typically offering postnatal care for the patient involved. In group II (FETO-group), mothers will, in between placement and removal of the balloon, thus carrying a fetus with obstructed airways, ideally remain under the care of our local fetal treatment center (further referred to as FETO center). As many as possible precautions are taken to avoid problems with balloon removal in case of earlier than expected delivery. Balloons are to be electively removed prior to 35 weeks. FETO centers will provide 24/24 hours and 7/7 days services for management of fetuses with obstructed airways, either in utero or during labor and delivery. Patients in the study and randomized to FETO, will be encouraged to stay near the FETO center. After reversal of the occlusion the patient will be referred to the tertiary care center where delivery and postnatal care will be undertaken. If the patient is not remaining at or close to the FETO center, the postnatal treatment center should organize likewise EXIT services.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hernia, Hernia, Diaphragmatic, Hernia, DIaphragmatic, Congenital, Pathological Conditions, Anatomical, Congenital Abnormalities, Congenital Diaphragmatic Hernia, Fetal Anomaly, Fetal Surgery, Pulmonary Hypoplasia
Keywords
CDH, Congenital Diaphragmatic Hernia, Fetal Tracheal Occlusion, FETO, plug-unplug, GoldBal2, Balloon, Goldvalve Balloon, TOTAL

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standardized postnatal care (Expectant)
Arm Type
Other
Arm Description
Mothers will be expectantly managed during pregnancies and babies receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website.
Arm Title
Prenatal Intervention (FETO)
Arm Type
Experimental
Arm Description
Patients will undergo fetoscopic endoluminal tracheal occlusion and ideally prenatal reversal of the occlusion followed by standardized postnatal care as in the expectant . In this study FETO (where GoldBal2 detachable balloon and Baltaccidbpe100 Delivery Catheter are used) is to be done between 30 weeks plus 0 day and 31 weeks plus 6 days and removal of the balloon at 34 weeks plus 0 day to 34 weeks plus 6 days.
Intervention Type
Device
Intervention Name(s)
GoldBal2 detachable balloon
Intervention Description
Placement of the balloon using the plug/unplug method.
Intervention Type
Device
Intervention Name(s)
Baltaccidbpe100 Delivery Catheter
Intervention Description
The catheter assists with implanting the balloon in the plug/unplug method.
Intervention Type
Other
Intervention Name(s)
Standardized postnatal care
Intervention Description
After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622
Primary Outcome Measure Information:
Title
Proportion of Neonate Survival at Discharge From Hospital
Description
The null hypothesis to be tested is that there is no difference in survival between fetuses managed expectantly during pregnancy versus those undergoing antenatal therapy (FETO).
Time Frame
At hospital discharge, an average of 1.5 months
Title
Participants Requiring Supplemental Oxygen
Description
The number of survivors requiring supplemental oxygen at 6 months of age
Time Frame
At 6 months of age
Secondary Outcome Measure Information:
Title
Grade of Oxygen Dependency
Description
Measured as FiO2 (oxygen) amount required as a grade (0-III) with Grade 0 indicating the best outcome and Grade III indicating the worst outcome. Grade 0 = No Bronchopulmonary Dysplasia (BPD); Grade I = FiO2 21% or room air; Grade II = FiO2 22-29%; Grade III = FiO2 >29%, CPAP or mechanical ventilation.
Time Frame
at 6 months of age
Title
Occurrence of Severe Pulmonary Hypertension
Description
Occurrence of severe pulmonary hypertension in the neonatal period.
Time Frame
During the first 4 weeks of life (neonatal period).
Title
ECMO (Extracorporeal Membrane Oxygenation) Support
Description
Need for extracorporeal membrane oxygenation (ECMO) in the neonatal period
Time Frame
Neonatal period (during the first 4 weeks of life)
Title
CDH Defect Size
Description
Postnatal grade classification (A-D) using CDH study group standardized system with A being the smallest defects and D being the largest defects. A = Defect entirely surrounded by muscle; B = Small (<50%) portion of the chest wall devoid of diaphragm tissue; C = Large (>50%) portion of the chest wall devoid of diaphragm tissue; D = Complete or near complete absence of the diaphragm.
Time Frame
Measured in neonate at delivery by MRI and/or ultrasound
Title
Number of Days in the NICU
Description
Length of stay in the neonatal intensive care unit measured in days
Time Frame
At the time of discharge from the NICU, an average of 1.5 months
Title
Ventilatory Support
Description
Length of time participants required ventilator support measured in days.
Time Frame
During the first 4 weeks of life (neonatal period)
Title
Number of Subjects With Periventricular Leukomalacia (PVL)
Description
As measured by presence in medical record ≤ 2 months postnatally by ultrasound (yes/no)
Time Frame
During first 2 months of life
Title
Neonatal Sepsis
Description
As measured by presence in medical record
Time Frame
During the first 4 weeks of life (neonatal period)
Title
Intraventricular Hemorrhage
Description
Measured as presence in neonate during first month by MRI and/or ultrasound.
Time Frame
During first month of life
Title
Retinopathy of Prematurity
Description
Postnatal grade classification presence of grade III or higher using standardized system (yes/no)
Time Frame
At the time of discharge from the NICU, an average of 1.5 months
Title
Days to Full Enteral Feeding
Description
The number of days until full enteral feeding
Time Frame
At hospital discharge, an average of 1.5 months
Title
Gastroesophageal Reflux
Description
Presence of reflux above 1/3 of esophagus on clinically indicated radiologic exam
Time Frame
At the time of discharge from the NICU, an average of 1.5 months
Title
CDH (Congenital Diaphragmatic Hernia) Surgery Repair
Description
How many days from birth until the surgery is performed to repair the defect.
Time Frame
From the time of birth until discharge from the NICU
Title
Use of Patch in CDH Repair
Description
The number of participants who had a patch used in the repair of the CDH defect.
Time Frame
At the time of the surgical repair postnatally, up to 3 days postnatal
Title
Survival
Description
The number of participants that survived to 24 months of age
Time Frame
At 24 months of age

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged 18 years or more, who are able to consent, Singleton pregnancy, Chromosomally normal fetus, Gestation at randomization prior to 31 weeks plus 5 days or so that occlusion is done at the latest on 31 weeks plus 6 days, Fetus is estimated to have moderate pulmonary hypoplasia, defined prenatally as: • O/E LHR 25-34.9% (included; irrespective of the position of the liver) • O/E LHR 35-44.9% (included) with intrathoracic liver herniation as determined by ultrasound or MRI. The O/E LHR will be determined by the FETO centers as follows: Measurement of the contralateral lung area preferentially by the tracing method at the 4-chamber view of the heart; if by other method adjusted normative ranges must be used. Measurement of the head circumference at the standard biparietal view of the head The observed lung area: calculation of the LHR as the ratio of the measurements of the lung area to head circumference The expected lung area is the lung area of a normal gestational age match, as determined by the head circumference of the index case in a normogram established for the same measurement method (tracing method in this case). A calculator for this will be available on the website of the study. Calculation of the observed over expected lung area, Acceptance of randomization and the consequences for the further management during pregnancy and thereafter, this includes the required observation following FETO surgery, which lasts up to 4 weeks after balloon is in place, The patients must undertake the responsibility for either remaining close to, or at the FETO center, or being able to travel swiftly and within acceptable time interval to the FETO center until the balloon is removed. Intended postnatal treatment center must subscribe to suggested guidelines for "standardized postnatal treatment," and Provide written consent to participate. Fetus with no major anomalies that would impact the clinical course or outcomes. Exclusion Criteria: Maternal contraindication to fetoscopic surgery or severe medical condition in pregnancy that make fetal intervention risky, Technical limitations precluding fetoscopic surgery, such as severe maternal obesity, uterine fibroids or potentially others, not anticipated at the time of writing this protocol, Preterm labor, cervix shortened (<15 mm at randomization) or uterine anomaly strongly predisposing to preterm labor, placenta previa, Patient age less than 18 years, Psychosocial ineligibility, precluding consent, Diaphragmatic hernia: right-sided or bilateral, major anomalies, isolated left-sided outside the O/E LHR limits for the inclusion criteria, and Patient refusing randomization, to comply with required 4-week observation after balloon placement, or to comply with return to FETO center during the time period the airways are occluded or for elective removal of the balloon. Patient allergic to latex.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Belfort, MD, PhD
Organizational Affiliation
Baylor College of Medicine - Texas Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Baylor College of Medicine/Texas Children's Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
17587219
Citation
Jani J, Nicolaides KH, Keller RL, Benachi A, Peralta CF, Favre R, Moreno O, Tibboel D, Lipitz S, Eggink A, Vaast P, Allegaert K, Harrison M, Deprest J; Antenatal-CDH-Registry Group. Observed to expected lung area to head circumference ratio in the prediction of survival in fetuses with isolated diaphragmatic hernia. Ultrasound Obstet Gynecol. 2007 Jul;30(1):67-71. doi: 10.1002/uog.4052.
Results Reference
background
PubMed Identifier
18844275
Citation
Jani JC, Benachi A, Nicolaides KH, Allegaert K, Gratacos E, Mazkereth R, Matis J, Tibboel D, Van Heijst A, Storme L, Rousseau V, Greenough A, Deprest JA; Antenatal-CDH-Registry group. Prenatal prediction of neonatal morbidity in survivors with congenital diaphragmatic hernia: a multicenter study. Ultrasound Obstet Gynecol. 2009 Jan;33(1):64-9. doi: 10.1002/uog.6141.
Results Reference
background
PubMed Identifier
15287047
Citation
Deprest J, Gratacos E, Nicolaides KH; FETO Task Group. Fetoscopic tracheal occlusion (FETO) for severe congenital diaphragmatic hernia: evolution of a technique and preliminary results. Ultrasound Obstet Gynecol. 2004 Aug;24(2):121-6. doi: 10.1002/uog.1711. Erratum In: Ultrasound Obstet Gynecol. 2004 Oct;24(5):594.
Results Reference
background
Citation
Jani J, Nicolaides K, Gratacos E, et al. 558: Short term neonatal morbidity in severe left-sided congenital diaphragmatic hernia treated by tracheal occlusion before 30 weeks. Am J Obstet Gynecol Dec;197(6),Supplement:S162.
Results Reference
background
PubMed Identifier
16769018
Citation
Jani JC, Nicolaides KH, Gratacos E, Vandecruys H, Deprest JA; FETO Task Group. Fetal lung-to-head ratio in the prediction of survival in severe left-sided diaphragmatic hernia treated by fetal endoscopic tracheal occlusion (FETO). Am J Obstet Gynecol. 2006 Dec;195(6):1646-50. doi: 10.1016/j.ajog.2006.04.004. Epub 2006 Jun 12.
Results Reference
background
PubMed Identifier
19658113
Citation
Jani JC, Nicolaides KH, Gratacos E, Valencia CM, Done E, Martinez JM, Gucciardo L, Cruz R, Deprest JA. Severe diaphragmatic hernia treated by fetal endoscopic tracheal occlusion. Ultrasound Obstet Gynecol. 2009 Sep;34(3):304-10. doi: 10.1002/uog.6450.
Results Reference
background
PubMed Identifier
19508989
Citation
Cannie MM, Jani JC, De Keyzer F, Allegaert K, Dymarkowski S, Deprest J. Evidence and patterns in lung response after fetal tracheal occlusion: clinical controlled study. Radiology. 2009 Aug;252(2):526-33. doi: 10.1148/radiol.2522081955. Epub 2009 Jun 9.
Results Reference
background
PubMed Identifier
20980772
Citation
Reiss I, Schaible T, van den Hout L, Capolupo I, Allegaert K, van Heijst A, Gorett Silva M, Greenough A, Tibboel D; CDH EURO Consortium. Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: the CDH EURO Consortium consensus. Neonatology. 2010;98(4):354-64. doi: 10.1159/000320622. Epub 2010 Oct 27.
Results Reference
background
PubMed Identifier
26692079
Citation
Snoek KG, Capolupo I, van Rosmalen J, Hout Lde J, Vijfhuize S, Greenough A, Wijnen RM, Tibboel D, Reiss IK; CDH EURO Consortium. Conventional Mechanical Ventilation Versus High-frequency Oscillatory Ventilation for Congenital Diaphragmatic Hernia: A Randomized Clinical Trial (The VICI-trial). Ann Surg. 2016 May;263(5):867-74. doi: 10.1097/SLA.0000000000001533.
Results Reference
background
PubMed Identifier
18845492
Citation
Deprest JA, Flemmer AW, Gratacos E, Nicolaides K. Antenatal prediction of lung volume and in-utero treatment by fetal endoscopic tracheal occlusion in severe isolated congenital diaphragmatic hernia. Semin Fetal Neonatal Med. 2009 Feb;14(1):8-13. doi: 10.1016/j.siny.2008.08.010. Epub 2008 Oct 8.
Results Reference
background
Citation
Jani J, Benachi A, Mitanchez D, et al. 2006. Lung-to-head ratio and liver position to predict neonatal morbidity in fetuses with isolated congenital diaphragmatic hernia: A multicenter study. Am Journal Obstet Gynecol 195(6); Supplement:S60.
Results Reference
background
PubMed Identifier
16774297
Citation
Ostrea EM, Villanueva-Uy ET, Natarajan G, Uy HG. Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management. Paediatr Drugs. 2006;8(3):179-88. doi: 10.2165/00148581-200608030-00004.
Results Reference
background
PubMed Identifier
17766505
Citation
Congenital Diaphragmatic Hernia Study Group; Lally KP, Lally PA, Lasky RE, Tibboel D, Jaksic T, Wilson JM, Frenckner B, Van Meurs KP, Bohn DJ, Davis CF, Hirschl RB. Defect size determines survival in infants with congenital diaphragmatic hernia. Pediatrics. 2007 Sep;120(3):e651-7. doi: 10.1542/peds.2006-3040.
Results Reference
background
PubMed Identifier
17177265
Citation
Gallot D, Boda C, Ughetto S, Perthus I, Robert-Gnansia E, Francannet C, Laurichesse-Delmas H, Jani J, Coste K, Deprest J, Labbe A, Sapin V, Lemery D. Prenatal detection and outcome of congenital diaphragmatic hernia: a French registry-based study. Ultrasound Obstet Gynecol. 2007 Mar;29(3):276-83. doi: 10.1002/uog.3863.
Results Reference
background
PubMed Identifier
10986445
Citation
Deprest JA, Evrard VA, Verbeken EK, Perales AJ, Delaere PR, Lerut TE, Flageole H. Tracheal side effects of endoscopic balloon tracheal occlusion in the fetal lamb model. Eur J Obstet Gynecol Reprod Biol. 2000 Sep;92(1):119-26. doi: 10.1016/s0301-2115(00)00435-8.
Results Reference
background
PubMed Identifier
11083424
Citation
Chiba T, Albanese CT, Farmer DL, Dowd CF, Filly RA, Machin GA, Harrison M. Balloon tracheal occlusion for congenital diaphragmatic hernia: experimental studies. J Pediatr Surg. 2000 Nov;35(11):1566-70. doi: 10.1053/jpsu.2000.18311.
Results Reference
background
Links:
URL
http://www.TOTALtrial.eu
Description
Information for the public and healthcare providers.
URL
http://www.euroCDH.org
Description
Information for the public and healthcare providers.

Learn more about this trial

'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial

We'll reach out to this number within 24 hrs